In 2022, the FDA granted fast track designation to enobosarm for AR+, ER+, HER2- metastatic breast cancer. Although a trial on AR positive triple negative breast cancer (which is ER-) was ended early due to lack of efficacy, enobosarm showed benefits in some patients with ER+, AR+ breast cancer in a phase II study. As of 2023update, there are no SARMs which have been approved for therapeutic use by the United States Food and Drug Administration or the European Medicines Agency. Teens are targeted on social media with marketing promoting use of SARMs to increase muscle and athletic performance. The "overdose" risk is more about taking high doses for an extended time period for body building or performance enhancement. Men may develop testicular atrophy, infertility and enlarged breast tissue. Long-term effects may include risk of heart attack or stroke, permanent liver damage, and increased risk of tendon rupture. Short-term effects include acute liver injury, increased blood pressure and heart rate, chest pain, psychological effects (such as mood swings, psychosis, irritability, anxiety), sleep disturbance, fatigue, acne, and hair loss). SARMs are not approved by the FDA or World Anti-Doping Agency. The theory is that at these lower doses, you get tissue-selective anabolic signaling without triggering meaningful HPTA suppression. Selective androgen receptor modulators (SARMs) are used for their anabolic effects and have fewer side effects than traditional androgens. SARMs activate androgen receptors, but with lower efficacy than testosterone. Five years ago, SARMs were the frontier—people treated them as miracle compounds that delivered anabolic effects without testosterone’s downsides. Besides, this binding may also impact the patterns linked with muscle hypertrophy, bone integrity, and libido during the experiment. In bone tissue, they affect osteoblast activity, which impacts osteoporosis (bone loss) in experimental models. In case of low testosterone levels, the condition is known as hypogonadism. Recently, the FDA approved an oral TRT for hypogonadism called Tlando. Several small studies are focusing on breast cancer, prostate, stress urinary incontinence, and sarcopenia. However, TRT can have several virilizing effects, making alternative treatments friendlier for some research applications. These include things such as male hair patterns and skeletal muscle growth.
